LPL Financial LLC Has $667,000 Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO)

LPL Financial LLC boosted its holdings in shares of Sutro Biopharma, Inc. (NASDAQ:STRO) by 34.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 362,232 shares of the company’s stock after acquiring an additional 92,333 shares during the quarter. LPL Financial LLC owned 0.44% of Sutro Biopharma worth $667,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of STRO. Barclays PLC raised its holdings in shares of Sutro Biopharma by 385.3% during the third quarter. Barclays PLC now owns 273,019 shares of the company’s stock worth $944,000 after acquiring an additional 216,757 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Sutro Biopharma by 7.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,856,956 shares of the company’s stock worth $6,426,000 after purchasing an additional 132,015 shares in the last quarter. Thrivent Financial for Lutherans acquired a new stake in shares of Sutro Biopharma during the 4th quarter valued at about $178,000. State Street Corp grew its stake in shares of Sutro Biopharma by 5.2% in the 3rd quarter. State Street Corp now owns 1,647,162 shares of the company’s stock valued at $5,699,000 after buying an additional 81,855 shares in the last quarter. Finally, Sei Investments Co. acquired a new position in Sutro Biopharma in the fourth quarter worth approximately $104,000. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Stock Performance

NASDAQ STRO opened at $0.72 on Wednesday. The stock has a 50-day simple moving average of $1.03 and a 200 day simple moving average of $2.07. Sutro Biopharma, Inc. has a twelve month low of $0.52 and a twelve month high of $5.17. The stock has a market capitalization of $61.15 million, a PE ratio of -0.45 and a beta of 1.70.

Sutro Biopharma (NASDAQ:STRO) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($2.96) EPS for the quarter, missing the consensus estimate of ($0.86) by ($2.10). Sutro Biopharma had a negative return on equity of 101.89% and a negative net margin of 77.01%. The business had revenue of $14.00 million during the quarter, compared to the consensus estimate of $10.44 million. During the same period in the prior year, the firm earned ($1.78) earnings per share. As a group, equities research analysts forecast that Sutro Biopharma, Inc. will post -2.92 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on the stock. Piper Sandler set a $2.00 target price on shares of Sutro Biopharma in a research report on Friday, March 14th. HC Wainwright reiterated a “neutral” rating and issued a $2.00 price objective (down from $12.00) on shares of Sutro Biopharma in a report on Monday, March 17th. Wedbush lowered Sutro Biopharma from an “outperform” rating to a “neutral” rating and cut their target price for the company from $8.00 to $2.00 in a report on Friday, March 14th. Citizens Jmp downgraded Sutro Biopharma from an “outperform” rating to a “market perform” rating in a research note on Friday, March 14th. Finally, Bank of America lowered Sutro Biopharma from a “buy” rating to an “underperform” rating and lowered their price objective for the company from $11.00 to $1.00 in a report on Friday, March 14th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, Sutro Biopharma presently has a consensus rating of “Hold” and a consensus price target of $6.63.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.